Antibody-drug Conjugates (ADCs) are cutting-edge treatments that join monoclonal antibodies with strong cytotoxic drugs using special ADC linkers. The success of ADCs depends a lot on groundbreaking ADC linker technologies. These technologies make sure the payload sticks to the antibody stays stable while circulating, and releases the drug in a controlled way at the target spot. We aim to push ADC development forward by creating next-gen ADC linkers and coming up with new linker solutions. We focus on making ADC programs more precise, stable, and effective in treating diseases.
Boasting a range of over 1000 ADC linker products, we give researchers plenty of top-notch choices to suit their needs. What's more, our broad customization options let us provide personalized ADC linker answers making sure they fit with what each ADC project requires.